Cargando…

Gene-agnostic approaches to treating inherited retinal degenerations

Most patients with inherited retinal degenerations (IRDs) have been waiting for treatments that are “just around the corner” for decades, with only a handful of seminal breakthroughs happening in recent years. Highlighting the difficulties in the quest for curative therapeutics, Luxturna required 16...

Descripción completa

Detalles Bibliográficos
Autores principales: Chew, Lindsey A., Iannaccone, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133473/
https://www.ncbi.nlm.nih.gov/pubmed/37123404
http://dx.doi.org/10.3389/fcell.2023.1177838
_version_ 1785031572944060416
author Chew, Lindsey A.
Iannaccone, Alessandro
author_facet Chew, Lindsey A.
Iannaccone, Alessandro
author_sort Chew, Lindsey A.
collection PubMed
description Most patients with inherited retinal degenerations (IRDs) have been waiting for treatments that are “just around the corner” for decades, with only a handful of seminal breakthroughs happening in recent years. Highlighting the difficulties in the quest for curative therapeutics, Luxturna required 16 years of development before finally obtaining United States Food and Drug Administration (FDA) approval and its international equivalents. IRDs are both genetically and phenotypically heterogeneous. While this diversity offers many opportunities for gene-by-gene precision medicine-based approaches, it also poses a significant challenge. For this reason, alternative (or parallel) strategies to identify more comprehensive, across-the-board therapeutics for the genetically and phenotypically diverse IRD patient population are very appealing. Even when gene-specific approaches may be available and become approved for use, many patients may have reached a disease stage whereby these approaches may no longer be viable. Thus, alternate visual preservation or restoration therapeutic approaches are needed at these stages. In this review, we underscore several gene-agnostic approaches that are being developed as therapeutics for IRDs. From retinal supplementation to stem cell transplantation, optogenetic therapy and retinal prosthetics, these strategies would bypass at least in part the need for treating every individual gene or mutation or provide an invaluable complement to them. By considering the diverse patient population and treatment strategies suited for different stages and patterns of retinal degeneration, gene agnostic approaches are very well poised to impact favorably outcomes and prognosis for IRD patients.
format Online
Article
Text
id pubmed-10133473
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101334732023-04-28 Gene-agnostic approaches to treating inherited retinal degenerations Chew, Lindsey A. Iannaccone, Alessandro Front Cell Dev Biol Cell and Developmental Biology Most patients with inherited retinal degenerations (IRDs) have been waiting for treatments that are “just around the corner” for decades, with only a handful of seminal breakthroughs happening in recent years. Highlighting the difficulties in the quest for curative therapeutics, Luxturna required 16 years of development before finally obtaining United States Food and Drug Administration (FDA) approval and its international equivalents. IRDs are both genetically and phenotypically heterogeneous. While this diversity offers many opportunities for gene-by-gene precision medicine-based approaches, it also poses a significant challenge. For this reason, alternative (or parallel) strategies to identify more comprehensive, across-the-board therapeutics for the genetically and phenotypically diverse IRD patient population are very appealing. Even when gene-specific approaches may be available and become approved for use, many patients may have reached a disease stage whereby these approaches may no longer be viable. Thus, alternate visual preservation or restoration therapeutic approaches are needed at these stages. In this review, we underscore several gene-agnostic approaches that are being developed as therapeutics for IRDs. From retinal supplementation to stem cell transplantation, optogenetic therapy and retinal prosthetics, these strategies would bypass at least in part the need for treating every individual gene or mutation or provide an invaluable complement to them. By considering the diverse patient population and treatment strategies suited for different stages and patterns of retinal degeneration, gene agnostic approaches are very well poised to impact favorably outcomes and prognosis for IRD patients. Frontiers Media S.A. 2023-04-13 /pmc/articles/PMC10133473/ /pubmed/37123404 http://dx.doi.org/10.3389/fcell.2023.1177838 Text en Copyright © 2023 Chew and Iannaccone. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Chew, Lindsey A.
Iannaccone, Alessandro
Gene-agnostic approaches to treating inherited retinal degenerations
title Gene-agnostic approaches to treating inherited retinal degenerations
title_full Gene-agnostic approaches to treating inherited retinal degenerations
title_fullStr Gene-agnostic approaches to treating inherited retinal degenerations
title_full_unstemmed Gene-agnostic approaches to treating inherited retinal degenerations
title_short Gene-agnostic approaches to treating inherited retinal degenerations
title_sort gene-agnostic approaches to treating inherited retinal degenerations
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133473/
https://www.ncbi.nlm.nih.gov/pubmed/37123404
http://dx.doi.org/10.3389/fcell.2023.1177838
work_keys_str_mv AT chewlindseya geneagnosticapproachestotreatinginheritedretinaldegenerations
AT iannacconealessandro geneagnosticapproachestotreatinginheritedretinaldegenerations